Does the media prefer AQST or BHC?

In the previous week, Bausch Health Cos had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 5 mentions for Bausch Health Cos and 2 mentions for Aquestive Therapeutics. Bausch Health Cos' average media sentiment score of 0.59 beat Aquestive Therapeutics' score of 0.45 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AQST or MLYS?

In the previous week, Mineralys Therapeutics had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.45 beat Mineralys Therapeutics' score of 0.42 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor TRLV or AQST?

In the previous week, Trulieve Cannabis had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Trulieve Cannabis and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.45 beat Trulieve Cannabis' score of 0.13 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is URGN or AQST more profitable?

Urogen Pharma has a net margin of -51.73% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets Urogen Pharma -51.73% N/A -43.79% Aquestive Therapeutics -144.63% N/A -52.40%

Does the media favor URGN or AQST?

In the previous week, Urogen Pharma had 2 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Urogen Pharma and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.45 beat Urogen Pharma's score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aquestive Therapeutics (AQST) Competitors

$4.78 +0.02 (+0.42%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.78 +0.00 (+0.10%)

As of 10/9/2026 07:46 PM Eastern

Compare

AQST vs. BHC, PBH, MLYS, TRLV, and URGN

Should you buy Aquestive Therapeutics stock or one of its competitors? Aquestive Therapeutics's main competitors and comparable companies include Bausch Health Cos (BHC), Prestige Consumer Healthcare (PBH), Mineralys Therapeutics (MLYS), Trulieve Cannabis (TRLV), and Urogen Pharma (URGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aquestive Therapeutics compare to Bausch Health Cos?

Aquestive Therapeutics (NASDAQ:AQST) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Bausch Health Cos has a net margin of -10.12% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Aquestive Therapeutics presently has a consensus price target of $8.60, suggesting a potential upside of 79.92%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 32.34%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14

In the previous week, Bausch Health Cos had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 5 mentions for Bausch Health Cos and 2 mentions for Aquestive Therapeutics. Bausch Health Cos' average media sentiment score of 0.59 beat Aquestive Therapeutics' score of 0.45 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A
Bausch Health Cos	$10.27B	0.22	$157M	-$2.96	N/A

Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Bausch Health Cos beats Aquestive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Aquestive Therapeutics' net margin of -144.63%. Prestige Consumer Healthcare's return on equity of 11.39% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Prestige Consumer Healthcare has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.10	$190.30M	$3.57	13.50
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A

Prestige Consumer Healthcare currently has a consensus target price of $67.67, suggesting a potential upside of 40.40%. Aquestive Therapeutics has a consensus target price of $8.60, suggesting a potential upside of 79.92%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 2 mentions for Aquestive Therapeutics and 1 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.49 beat Aquestive Therapeutics' score of 0.45 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prestige Consumer Healthcare has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Summary

Prestige Consumer Healthcare beats Aquestive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Mineralys Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

In the previous week, Mineralys Therapeutics had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.45 beat Mineralys Therapeutics' score of 0.42 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aquestive Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Aquestive Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mineralys Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Aquestive Therapeutics currently has a consensus target price of $8.60, suggesting a potential upside of 79.92%. Mineralys Therapeutics has a consensus target price of $48.80, suggesting a potential upside of 108.81%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Aquestive Therapeutics beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Trulieve Cannabis presently has a consensus price target of $15.00, suggesting a potential upside of 41.02%. Aquestive Therapeutics has a consensus price target of $8.60, suggesting a potential upside of 79.92%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Trulieve Cannabis has a net margin of -41.55% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Trulieve Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

32.5% of Aquestive Therapeutics shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Trulieve Cannabis had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Trulieve Cannabis and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.45 beat Trulieve Cannabis' score of 0.13 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics has lower revenue, but higher earnings than Trulieve Cannabis. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.18B	1.73	-$116.38M	$0.11	96.70
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A

Summary

Aquestive Therapeutics beats Trulieve Cannabis on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Urogen Pharma had 2 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Urogen Pharma and 2 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.45 beat Urogen Pharma's score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	16.40	-$153.49M	-$1.98	N/A
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A

Urogen Pharma presently has a consensus price target of $52.38, indicating a potential upside of 42.21%. Aquestive Therapeutics has a consensus price target of $8.60, indicating a potential upside of 79.92%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Urogen Pharma has a net margin of -51.73% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Urogen Pharma and Aquestive Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$597.43M	$12.34B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	-7.35	797.58	274.13	26.16
Price / Sales	13.47	754.39	590.44	94.78
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	-17.07	10.71	11.21	6.34
Net Income	-$83.78M	$2.84B	$3.50B	$381.90M
7 Day Performance	5.05%	-0.94%	-0.92%	-1.41%
1 Month Performance	-4.21%	-4.92%	-4.46%	-3.48%
1 Year Performance	-26.91%	-4.14%	6.94%	1.16%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	1.7905 of 5 stars	$4.78 +0.4%	$8.60 +79.9%	-28.6%	$597.43M	$44.54M	N/A	147	Positive News
BHC Bausch Health Cos	3.2398 of 5 stars	$5.81 +1.3%	$8.00 +37.8%	-5.5%	$2.17B	$10.27B	N/A	20,300	Analyst Forecast Options Volume
PBH Prestige Consumer Healthcare	3.9353 of 5 stars	$45.35 +1.3%	$67.67 +49.2%	-23.1%	$2.15B	$1.09B	12.70	890
MLYS Mineralys Therapeutics	3.1851 of 5 stars	$23.63 -0.4%	$48.80 +106.5%	-40.7%	$2.09B	N/A	N/A	76	News Coverage
TRLV Trulieve Cannabis	3.6046 of 5 stars	$10.71 -1.5%	$15.00 +40.1%	N/A	$2.06B	$1.18B	N/A	5,000	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. BHC, PBH, MLYS, TRLV, and URGN

How does Aquestive Therapeutics compare to Bausch Health Cos?

Summary

How does Aquestive Therapeutics compare to Prestige Consumer Healthcare?

Summary

How does Aquestive Therapeutics compare to Mineralys Therapeutics?

Summary

How does Aquestive Therapeutics compare to Trulieve Cannabis?

Summary

How does Aquestive Therapeutics compare to Urogen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. BHC, PBH, MLYS, TRLV, and URGN

How does Aquestive Therapeutics compare to Bausch Health Cos?

Is AQST or BHC more profitable?

Do analysts recommend AQST or BHC?

Does the media prefer AQST or BHC?

Which has better valuation & earnings, AQST or BHC?

Which has more volatility & risk, AQST or BHC?

Do insiders & institutionals have more ownership in AQST or BHC?

Summary

How does Aquestive Therapeutics compare to Prestige Consumer Healthcare?

Is PBH or AQST more profitable?

Which has better earnings and valuation, PBH or AQST?

Do analysts recommend PBH or AQST?

Do insiders & institutionals believe in PBH or AQST?

Does the media favor PBH or AQST?

Which has more risk & volatility, PBH or AQST?

Summary

How does Aquestive Therapeutics compare to Mineralys Therapeutics?

Does the media prefer AQST or MLYS?

Which has stronger earnings & valuation, AQST or MLYS?

Which has more volatility & risk, AQST or MLYS?

Do insiders & institutionals hold more shares of AQST or MLYS?

Is AQST or MLYS more profitable?

Do analysts recommend AQST or MLYS?

Summary

How does Aquestive Therapeutics compare to Trulieve Cannabis?

Do analysts prefer TRLV or AQST?

Is TRLV or AQST more profitable?

Do insiders & institutionals hold more shares of TRLV or AQST?

Does the media favor TRLV or AQST?

Which has better earnings and valuation, TRLV or AQST?

Summary

How does Aquestive Therapeutics compare to Urogen Pharma?

Do insiders and institutionals have more ownership in URGN or AQST?

Does the media favor URGN or AQST?

Which has higher valuation and earnings, URGN or AQST?

Do analysts rate URGN or AQST?

Is URGN or AQST more profitable?

Which has more risk & volatility, URGN or AQST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools